EXPERIENCE OF RITUXIMAB TREATMENT IN A PATIENT WITH JUVENILE SCLERODERMA
https://doi.org/10.15690/vsp.v11i3.313
Abstract
A clinical case of severe juvenile scleroderma is represented in this article. The patient had a high activity and aggressive course of disease, he was resistant to steroid, cyclophosphomide and methotrexate therapy in combination with drugs, improving blood circulation. The authors describe the successful usage of chimeric monoclonal antibody against the protein CD20 — Rituximab. By the 4th week of the treatment the signs of intoxication and local manifestations of the disease (density and area of scleroderma patches) have diminished. By the 24th week the immunological markers of activity have become normal. Afore-mentioned clinical case demonstrates high efficacy of Rituximab in patient with severe course of juvenile scleroderma. By now the stage of clinical and laboratory remission has maintained for 52 weeks.
About the Authors
E. I. Alexeeva
Scientific Centre of Children Health RAMS, Moscow;
I.M. Setchenov First Moscow State Medical University
Russian Federation
Alekseeva Ekaterina Iosifovna, PhD, professor, Head of the Pediatric Faculty of I.M. Sechenov First MSMU, Head of the Rheumatologic Department of SCCH of RAMS
Russian Federation
Alekseeva Ekaterina Iosifovna, PhD, professor, Head of the Pediatric Faculty of I.M. Sechenov First MSMU, Head of the Rheumatologic Department of SCCH of RAMS
S. I. Valieva
Scientific Centre of Children Health RAMS, Moscow
Russian Federation
Russian Federation
T. M. Bzarova
Scientific Centre of Children Health RAMS, Moscow
Russian Federation
Russian Federation
K. B. Isaeva
Scientific Centre of Children Health RAMS, Moscow
Russian Federation
Russian Federation
R. V. Denisova
Scientific Centre of Children Health RAMS, Moscow
Russian Federation
Russian Federation
T. V. Sleptsova
Scientific Centre of Children Health RAMS, Moscow
Russian Federation
Russian Federation
E. V. Mitenko
Scientific Centre of Children Health RAMS, Moscow
Russian Federation
Russian Federation
References
1. Гусева Н. Г. Системная склеродермия и псевдосклеродермические синдромы. М.: Медицина. 1993. С. 267
2. Zulian F. Systemic sclerosis and localized scleroderma in childhood. Rheummatic Diseas Clinics of North America. 2008; 34: 239–255.
3. ZulianF., Avcin T. et al. The juvenile scleroderma international database: an instrument for improving research and standard of care in rare disease of childhood. Ann. of the Rheumatic Disease. 2007; 66 (11): 230.
4. Martini G., Foelvari I., Russo R. et al. Systemic sclerosis in childhood: clinical and epidemiological features in 750 children. An. International study. J. Rheumatol. 2006; 45: 614–620.
5. Струков А. И., Бегларян А. Г. Патологическая анатомия и патогенез коллагеновых болезней. М.: Медицина. 1963. С. 217–248.
6. Сигидин Я. А., Гусева Н.Г., Иванов М. М. Диффузные болезни соединительной ткани. Руководство для врачей. М.: Медицина. 2004. С. 341–348.
7. Высоцкий Г. Я. Системная и очаговая склеродермия. Л.: Медицина. 1971. С. 236.
8. Уварова Н. Н. Клиническая картина и течение системной склеродермии у детей. Автореф. дис. … докт. мед. наук. Москва. 1989.
9. Sakkas L. I., Platsoucas C. D. Is systemic sclerosis an antigendriven T cells diseases? Arthritis Rheum. 1992; 50: 1721–1133.
10. Abraham D. J., Varga J. Scleroderma: from cell and molecular mechanism to disease models. Trends immunol. 2005; 26: 587–595.
11. Prescot R. J. et al. Sequencial dermal microvascular and perivascular changes in the development of scleroderma. J. Pathol. 1992; 166: 255–263.
12. Skaas L. I. et al. Increased levels of alternatively spliced interleukin 4 (IL4) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis. Clin. Diagn. Lab. Immunol. 1999; 6: 660–664.
13. Mavali C. et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am. J. Pathol. 1997; 151: 1751–1758.
14. Chizollini C. et al. Systemic sclerosis Th2 cells inhibit collagen production in dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum. 2003; 48: 2593–2604.
15. Sato S. et al. Altered blood B lympho- cyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum. 2004; 1918–1927.
16. Balint G., Gergely P. Clinical immunotoxicity of antirheumatic drugs. Inflamm. Res. 1996; 45: 91–95.
17. Flato B., Vinje O., Forre O. Toxicity of antirheumatic and antiinflammatory drugs in children. Clin. Rheumatol. 1998; 17: 505–510.
18. Noorchashm H., Noorchashm N., Kern J. et al. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes. 1997; 46: 941–946.
19. Chan O. T., Hannum L. G., Haberman A. M. et al. A novel mouse with B cells but lacking serum antibody reveals an antibodyindependent role for B cells in murine lupus. J. Exp. Med. 1999; 189: 1639–1648.
20. Takemura S., Braun A., Crowson C. et al. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 2001; 167: 1072–1080.
21. O’Neill S. K., Shlomchik M. J., Glant T. T. et al. Antigenspecific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J. Immunol. 2005; 174: 3781–3788.
22. Balint G., Gergely P. Clinical immunotoxicity of antirheumatic drugs. Inflamm. Res. 1996; 45: 91–95.
23. Flato B., Vinje O., Forre O. Toxicity of antirheumatic and antiinflammatory drugs in children. Clin. Rheumatol. 1998; 17: 505–510.
24. Anolik J. H., Barnard J., Cappione A. et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004; 50: 3580–3590.
25. McGonagle D. et al. Successful treatment of resistant scleroderma- associated lung disease with rituximab. Rheumatology. 2008; 47 (4): 552–553.
26. Adams A. B. et al. Cyclophosphamide and rituximab combination therapy for the treatment of Juvenile-onset scleroderma: 6 Patient Case Series. Proceeding of ACR/ARHP Annual Scientific Meeting. Washington. USA. 2006.
27. Lafyatis R., Kissin E., York M. et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009; 60 (2): 578–583.
28. Smith V. P., Van Praet J. T., Vandooren B. R. et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann. Rheum. Dis. 2008.
Review
For citations:
Alexeeva E.I., Valieva S.I., Bzarova T.M., Isaeva K.B., Denisova R.V., Sleptsova T.V., Mitenko E.V. EXPERIENCE OF RITUXIMAB TREATMENT IN A PATIENT WITH JUVENILE SCLERODERMA. Current Pediatrics. 2012;11(3):131-137. (In Russ.) https://doi.org/10.15690/vsp.v11i3.313
Views:
804
Email this article 
